Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Primidone
Drug ID BADD_D01840
Description Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]
Indications and Usage Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures.[L4645,L11112] In addition, it has also been studied and utilized as an effective management of essential tremor.[A39414,A39415,L4645]
Marketing Status approved; vet_approved
ATC Code N03AA03
DrugBank ID DB00794
KEGG ID D00474
MeSH ID D011324
PubChem ID 4909
TTD Drug ID D0U5RT
NDC Product Code 72888-045; 72888-046; 53746-544; 71610-590; 59348-0001; 42291-511; 50090-4083; 71610-191; 55111-876; 52817-117; 63629-7811; 71610-079; 62135-468; 0591-5321; 71335-1965; 72888-160; 17205-308; 49452-6020; 81066-0002; 42291-509; 68084-202; 68084-203; 71335-1158; 65162-544; 66490-691; 0527-1301; 0615-8206; 69575-4045; 66490-690; 72789-177; 53746-545; 72189-216; 72789-178; 17205-307; 50268-686; 51407-637; 51407-638; 65162-545; 69584-685; 0527-1231; 71610-005; 71610-540; 55111-477; 69584-684; 50268-687; 55111-476
UNII 13AFD7670Q
Synonyms Primidone | Liskantin | Mylepsinum | Resimatil | Desoxyphenobarbital | Mizodin | Mysoline | Apo-Primidone | Apo Primidone | Primaclone | Sertan | Misodine | Primidon Holsten
Chemical Information
Molecular Formula C12H14N2O2
CAS Registry Number 125-33-7
SMILES CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Anaemia01.03.02.001--
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Apathy19.04.04.002--Not Available
Aplasia03.02.01.002; 08.03.04.003--Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.001--Not Available
Arteriovenous fistula24.03.03.0010.000514%Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.001096%Not Available
Ataxia17.02.02.001; 08.01.02.0040.000342%
Completed suicide19.12.01.001; 08.04.01.0100.000685%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000342%
Depressed level of consciousness17.02.04.0020.000342%
Depression19.15.01.0010.000342%
Dermatitis23.03.04.002--Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness24.06.02.007; 02.11.04.006; 17.02.05.0030.001507%
Drug hypersensitivity10.01.01.0010.004246%Not Available
Drug ineffective08.06.01.0060.001918%Not Available
Dupuytren's contracture15.03.05.0100.000685%Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Emotional disorder19.04.02.005--Not Available
Epilepsy17.12.03.002--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.0020.000753%
Feeling abnormal08.01.09.0140.001747%Not Available
Flat affect19.04.01.004--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene